FDA advisory panel fails to endorse Capricor Duchenne treatment
· seekingalpha.com
FDA advisors voted 6-3 saying HOPE-3 data doesn’t strongly support Capricor’s deramiocel for DMD cardiomyopathy. Read more here.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
If you have an ad-blocker enabled you may be blocked from ...